|
Publications From Last Four Years
Whitehead RP, Unger JM, Flaherty LE, Eckhard JR, Taylor SA, Didolkar MS,
Samlowski W, Sondak VK. Evaluation of CI-980 in patients
with disseminated malignant melanoma and no prior chemotherapy: A Southwest
Oncology Group study. Invest New Drugs 19:239-243,2001.
Samlowski WE. Nitric oxide as a mediator of interleukin-2
induced cardiovascular toxicity and antitumor activity. In Salvemini D,
Billiar TR, Vodovotz Y (eds) Nitric oxide and inflammation. Birkhäuser
Publishing Ltd, Basel (2001), p249-27
Florell SR, Boucher KA, Holden JA, Meyer LA, Samlowski WE,
Cannon-Albright LA, Zone JJ, Leachman SA. Failure to detect differences
in proliferation status of nevi from CDKN2A mutation carriers and non-carriers.
J Invest Dermatol 118:386-387, 2002.
Houghton AN, Bloomer WD, Chu D, Coit, DG, Eisenberg BL, Guitart J,
Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Miller SJ, Reintgen
D, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Tarnatolo
S, Thompson JA, Urist MM, Walker MJ. NCCN Practice Guidelines in Oncology-v.1.2002:
Melanoma. National Comprehensive Cancer Network, Jenkinstown, PA (CD)(2002),
p 1-23.
Samlowski WE, Petersen R, Cuzzocrea S, Macarthur H,
Burton D, McGregor JR, Salvemini D. A nonpeptidyl mimic of superoxide
dismutase, M40403, inhibits dose-limiting hypotension associated with
IL-2 and increases its anti-tumor effects. Nature Medicine 9:750-755,
2003.
Salvemini D and Samlowski WE. Role of superoxide dismutase
in cancer. Nature Med 9:1103, 2003 (letter to editor).
Alexander A, Samlowski WE, Grossman D, Bruggers CS,
Harris RM, Zone JJ, Noyes RD, Bowen GM, Leachman SA. Metastatic Melanoma
in Pregnancy: Risk of Transplacental Metastases in the Infant. J Clin
Oncol 21:2179-2187, 2003.
Motzer RJ, Bahnson RR, Carducci MA, Fishman M, Hancock SL, Hauke RJ,
Hudes GR, Kantoff P, Kozlowski JM, Lange PH, Levine EG, Logothetis C,
Margolin KA, Robertson CN, Samlowski WE, Sandler H, Sheinfeld
J, Urban DA. NCCN Practice Guidelines in Oncology-v.1.2003: Kidney Cancer.
National Comprehensive Cancer Network, Jenkinstown, PA (CD)(2003), p 1-14.
Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE,
Beck JT, Tchekmedyian NS, Sondak VK. A phase II trial of vinorelbine tartarate
(Navelbine) in patients with disseminated malignant melanoma and one prior
systemic therapy: A Southwest Oncology Group study. Cancer 100:1699-1704,
2004.
Kwon OD, Yim CY, Jeong KS, Jung KY, McGregor JR, Bastian, NR and Samlowski
WE. Suppression of cytokine-inducible nitric oxide synthesis
during intraperitoneal Meth A tumor growth. J Vet Med Sci 66:357-365,
2004.
Whitehead RP, Benedetti JK, Abbruzzese JL, Ardalan B, Goodwin JW,
Balcerzak SP, Leichman CG, Samlowski WE, Lenz HJ, Macdonald
JS. A phase II pilot study of high-dose 24-hour continuous infusion of
5-FU and leukovorin and low-dose PALA in patients with pancreatic adenocarcinoma:
A Southwest Oncology Group Study. Invest New Drugs 22:335-341, 2004.
Stiff,PJ, Shpall EJ, Liu PY, Wilczynski SP, Callender NS, Scudder
SA, Jazieh A-R, Samlowski WE, McCoy J, Alberts DS. Randomized
phase II trial of two high-dose chemotherapy regimens with stem cell transplantation
for the treatment of advanced ovarian cancer in first remission or chemosensitive
relapsse: A Southwest Oncology Group study. Gynecol Oncol 94:98-106, 2004.
Bharadwaj JS, Blumenthal DT, Samlowski WE. Reversible
diplopia induced by high dose intravenous IL-2 therapy. Clin Adv Hematol
Oncol, 2:471-472, 2004.
Florell SR, Leachman SA, Boucher KM, Porter-Gill P, Erickson HP, Hart
M, Erickson J, Cannon-Albright LA, Pershing LK, Harris RM, Samlowski
WE, Brinton JP, Zone JJ, Meyer LJ. Longitudinal assessment of
the nevus phenotype in a melanoma kindred. J Invest Dermatol 123:576-582,
2004.
Houghton AN, Chu D, Coit, DG, Daud A, Dilawari RA, Guitart J, Halpern
A, Johnson TM, Kashani-Sabet M, Kraybill WG, Miller SJ, Mosca P, Ross
MI, Samlowski WE, Sener SF, Tanabe KK, Tarnatolo S, Thompson
JA, Urist MM, Walker MJ. The NCCN melanoma clinical practice guidelines.
JNCCN 2:46-61, 2004.
Houghton AN, Chu D, Coit, DG, Daud A, Dilawari RA, Guitart J, Halpern
A, Johnson TM, Kashani-Sabet M, Kraybill WG, Miller SJ, Mosca P, Ross
MI, Samlowski WE, Sener SF, Tanabe KK, Tarnatolo S, Thompson
JA, Urist MM, Walker MJ. NCCN Practice Guidelines in Oncology-v.1.2004:
Melanoma. National Comprehensive Cancer Network, Jenkinstown, PA (CD)(2004),
p 1-25.
Samlowski WE, Petersen R, McGregor JR, Kondapaneni
M, Salvemini D. Evaluation of a superoxide dismutase mimetic as an adjunct
to interleukin 2 based cancer therapy. in Therapeutic applications of
superoxide dismutase. Salvemini D and Cuzzocrea S, eds. Eurekah.com (2004)
p1-22.
Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill
P, Busby L, Wheeler R, Jones DA, Karpf AR. Phase I evalaution of a 7-day
continuous intravenous infusion of decitabine (5-aza-2’-deoxycitidine):
Inhibition of promoter-specific and global DNA methylation. J Clin Oncol
23:3897-3905, 2005.
Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR,
Kantoff P, Kuzel T, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili
R, Pohar K, Redman BG, Richey S, Robertson CN, Samlowski WE,
Sheinfeld J, Urban DA. NCCN Practice Guidelines in Oncology-v.1.2005:
Kidney Cancer. National Comprehensive Cancer Network, Jenkinstown, PA
(CD)(2005), p 1-16.
Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR,
Kantoff P, Kuzel T, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili
R, Pohar K, Redman BG, Richey S, Robertson CN, Samlowski WE,
Sheinfeld J, Urban DA. The NCCN kidney cancer clinical practice guidelines.
JNCCN 3:84-93, 2005.
Lewis TB, Robison JE, Bastien R, Milash B, Boucher K, Samlowski
WE, Leachman SA, Noyes RD, Wittwer CT, Perreard L, Bernard PS.
Molecular classification of melanoma using real-time quantitative RT-PCR
(in press: Cancer).
Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G,
Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, Zone JJ, Samlowski
WE, Leachman SA. Population based analysis of prognostic factors
and survival in familial melanoma. (in press J Clin Oncol).
|
